Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells

Sara Beji, Giuseppina Milano, Alessandro Scopece, Lucia Cicchillitti, Chiara Cencioni, Mario Picozza, Yuri D'Alessandra, Sarah Pizzolato, Matteo Bertolotti, Gabriella Spaltro, Angela Raucci, Giulia Piaggio, Giulio Pompilio, Maurizio C Capogrossi, Daniele Avitabile, Alessandra Magenta, Elisa Gambini

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Doxorubicin (DOXO) treatment is limited by its cardiotoxicity, since it causes cardiac-progenitor-cell depletion. Although the cardioprotective role of the stromal cell-derived factor-1/C-X-C chemokine receptor type 4 (SDF1/CXCR4) axis is well established, its involvement during DOXO-induced cardiotoxicity has never been investigated. We showed that in a mouse model of DOXO-induced cardiomyopathy, CXCR4+cells were increased in response to DOXO, mainly in human cardiac mesenchymal progenitor cells (CmPC), a subpopulation with regenerative potential. Our in vitro results showed a CXCR4 induction after 24 h of DOXO exposure in CmPC. SDF1 administration protected from DOXO-induced cell death and promoted CmPC migration. CXCR4 promoter analysis revealed zinc finger E-box binding homeobox 1 (ZEB1) binding sites. Upon DOXO treatment, ZEB1 binding decreased and RNA-polymerase-II increased, suggesting a DOXO-mediated transcriptional increase in CXCR4. Indeed, DOXO induced the upregulation of miR-200c, that directly targets ZEB1. SDF1 administration in DOXO-treated mice partially reverted the adverse remodeling, decreasing left ventricular (LV) end diastolic volume, LV ejection fraction and LV anterior wall thickness in diastole, recovering LV end systolic pressure and reducing±dP/dt. Moreover, in vivo administration of SDF1 partially reverted DOXO-induced miR-200c and p53 protein upregulation in mouse hearts. In addition, downmodulation of ZEB1 mRNA and protein by DOXO was significantly increased by SDF1. In keeping, p21 mRNA, that is induced by p53 and inhibited by ZEB1, is induced by DOXO treatment and is decreased by SDF1 administration. This study showed new players of the DOXO-induced cardiotoxicity, that can be exploited to ameliorate DOXO-associated cardiomyopathy.

Original languageEnglish
Pages (from-to)e3020
JournalCell Death and Disease
Volume8
Issue number8
DOIs
Publication statusPublished - Aug 24 2017

Fingerprint

Mesenchymal Stromal Cells
Doxorubicin
Up-Regulation
Zinc Finger E-box-Binding Homeobox 1
Cardiomyopathies
Stroke Volume
Chemokine CXCL12
CXC Chemokines
Messenger RNA
Diastole
RNA Polymerase II
Chemokine Receptors
Cell Movement
Proteins
Cell Death
Stem Cells

Keywords

  • Journal Article

Cite this

Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells. / Beji, Sara; Milano, Giuseppina; Scopece, Alessandro; Cicchillitti, Lucia; Cencioni, Chiara; Picozza, Mario; D'Alessandra, Yuri; Pizzolato, Sarah; Bertolotti, Matteo; Spaltro, Gabriella; Raucci, Angela; Piaggio, Giulia; Pompilio, Giulio; Capogrossi, Maurizio C; Avitabile, Daniele; Magenta, Alessandra; Gambini, Elisa.

In: Cell Death and Disease, Vol. 8, No. 8, 24.08.2017, p. e3020.

Research output: Contribution to journalArticle

Beji, Sara ; Milano, Giuseppina ; Scopece, Alessandro ; Cicchillitti, Lucia ; Cencioni, Chiara ; Picozza, Mario ; D'Alessandra, Yuri ; Pizzolato, Sarah ; Bertolotti, Matteo ; Spaltro, Gabriella ; Raucci, Angela ; Piaggio, Giulia ; Pompilio, Giulio ; Capogrossi, Maurizio C ; Avitabile, Daniele ; Magenta, Alessandra ; Gambini, Elisa. / Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells. In: Cell Death and Disease. 2017 ; Vol. 8, No. 8. pp. e3020.
@article{fe08e15e466e4b8bb8f2a96a9ebf3b38,
title = "Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells",
abstract = "Doxorubicin (DOXO) treatment is limited by its cardiotoxicity, since it causes cardiac-progenitor-cell depletion. Although the cardioprotective role of the stromal cell-derived factor-1/C-X-C chemokine receptor type 4 (SDF1/CXCR4) axis is well established, its involvement during DOXO-induced cardiotoxicity has never been investigated. We showed that in a mouse model of DOXO-induced cardiomyopathy, CXCR4+cells were increased in response to DOXO, mainly in human cardiac mesenchymal progenitor cells (CmPC), a subpopulation with regenerative potential. Our in vitro results showed a CXCR4 induction after 24 h of DOXO exposure in CmPC. SDF1 administration protected from DOXO-induced cell death and promoted CmPC migration. CXCR4 promoter analysis revealed zinc finger E-box binding homeobox 1 (ZEB1) binding sites. Upon DOXO treatment, ZEB1 binding decreased and RNA-polymerase-II increased, suggesting a DOXO-mediated transcriptional increase in CXCR4. Indeed, DOXO induced the upregulation of miR-200c, that directly targets ZEB1. SDF1 administration in DOXO-treated mice partially reverted the adverse remodeling, decreasing left ventricular (LV) end diastolic volume, LV ejection fraction and LV anterior wall thickness in diastole, recovering LV end systolic pressure and reducing±dP/dt. Moreover, in vivo administration of SDF1 partially reverted DOXO-induced miR-200c and p53 protein upregulation in mouse hearts. In addition, downmodulation of ZEB1 mRNA and protein by DOXO was significantly increased by SDF1. In keeping, p21 mRNA, that is induced by p53 and inhibited by ZEB1, is induced by DOXO treatment and is decreased by SDF1 administration. This study showed new players of the DOXO-induced cardiotoxicity, that can be exploited to ameliorate DOXO-associated cardiomyopathy.",
keywords = "Journal Article",
author = "Sara Beji and Giuseppina Milano and Alessandro Scopece and Lucia Cicchillitti and Chiara Cencioni and Mario Picozza and Yuri D'Alessandra and Sarah Pizzolato and Matteo Bertolotti and Gabriella Spaltro and Angela Raucci and Giulia Piaggio and Giulio Pompilio and Capogrossi, {Maurizio C} and Daniele Avitabile and Alessandra Magenta and Elisa Gambini",
year = "2017",
month = "8",
day = "24",
doi = "10.1038/cddis.2017.409",
language = "English",
volume = "8",
pages = "e3020",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells

AU - Beji, Sara

AU - Milano, Giuseppina

AU - Scopece, Alessandro

AU - Cicchillitti, Lucia

AU - Cencioni, Chiara

AU - Picozza, Mario

AU - D'Alessandra, Yuri

AU - Pizzolato, Sarah

AU - Bertolotti, Matteo

AU - Spaltro, Gabriella

AU - Raucci, Angela

AU - Piaggio, Giulia

AU - Pompilio, Giulio

AU - Capogrossi, Maurizio C

AU - Avitabile, Daniele

AU - Magenta, Alessandra

AU - Gambini, Elisa

PY - 2017/8/24

Y1 - 2017/8/24

N2 - Doxorubicin (DOXO) treatment is limited by its cardiotoxicity, since it causes cardiac-progenitor-cell depletion. Although the cardioprotective role of the stromal cell-derived factor-1/C-X-C chemokine receptor type 4 (SDF1/CXCR4) axis is well established, its involvement during DOXO-induced cardiotoxicity has never been investigated. We showed that in a mouse model of DOXO-induced cardiomyopathy, CXCR4+cells were increased in response to DOXO, mainly in human cardiac mesenchymal progenitor cells (CmPC), a subpopulation with regenerative potential. Our in vitro results showed a CXCR4 induction after 24 h of DOXO exposure in CmPC. SDF1 administration protected from DOXO-induced cell death and promoted CmPC migration. CXCR4 promoter analysis revealed zinc finger E-box binding homeobox 1 (ZEB1) binding sites. Upon DOXO treatment, ZEB1 binding decreased and RNA-polymerase-II increased, suggesting a DOXO-mediated transcriptional increase in CXCR4. Indeed, DOXO induced the upregulation of miR-200c, that directly targets ZEB1. SDF1 administration in DOXO-treated mice partially reverted the adverse remodeling, decreasing left ventricular (LV) end diastolic volume, LV ejection fraction and LV anterior wall thickness in diastole, recovering LV end systolic pressure and reducing±dP/dt. Moreover, in vivo administration of SDF1 partially reverted DOXO-induced miR-200c and p53 protein upregulation in mouse hearts. In addition, downmodulation of ZEB1 mRNA and protein by DOXO was significantly increased by SDF1. In keeping, p21 mRNA, that is induced by p53 and inhibited by ZEB1, is induced by DOXO treatment and is decreased by SDF1 administration. This study showed new players of the DOXO-induced cardiotoxicity, that can be exploited to ameliorate DOXO-associated cardiomyopathy.

AB - Doxorubicin (DOXO) treatment is limited by its cardiotoxicity, since it causes cardiac-progenitor-cell depletion. Although the cardioprotective role of the stromal cell-derived factor-1/C-X-C chemokine receptor type 4 (SDF1/CXCR4) axis is well established, its involvement during DOXO-induced cardiotoxicity has never been investigated. We showed that in a mouse model of DOXO-induced cardiomyopathy, CXCR4+cells were increased in response to DOXO, mainly in human cardiac mesenchymal progenitor cells (CmPC), a subpopulation with regenerative potential. Our in vitro results showed a CXCR4 induction after 24 h of DOXO exposure in CmPC. SDF1 administration protected from DOXO-induced cell death and promoted CmPC migration. CXCR4 promoter analysis revealed zinc finger E-box binding homeobox 1 (ZEB1) binding sites. Upon DOXO treatment, ZEB1 binding decreased and RNA-polymerase-II increased, suggesting a DOXO-mediated transcriptional increase in CXCR4. Indeed, DOXO induced the upregulation of miR-200c, that directly targets ZEB1. SDF1 administration in DOXO-treated mice partially reverted the adverse remodeling, decreasing left ventricular (LV) end diastolic volume, LV ejection fraction and LV anterior wall thickness in diastole, recovering LV end systolic pressure and reducing±dP/dt. Moreover, in vivo administration of SDF1 partially reverted DOXO-induced miR-200c and p53 protein upregulation in mouse hearts. In addition, downmodulation of ZEB1 mRNA and protein by DOXO was significantly increased by SDF1. In keeping, p21 mRNA, that is induced by p53 and inhibited by ZEB1, is induced by DOXO treatment and is decreased by SDF1 administration. This study showed new players of the DOXO-induced cardiotoxicity, that can be exploited to ameliorate DOXO-associated cardiomyopathy.

KW - Journal Article

U2 - 10.1038/cddis.2017.409

DO - 10.1038/cddis.2017.409

M3 - Article

C2 - 28837147

VL - 8

SP - e3020

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 8

ER -